Page last updated: 2024-12-11

11,12,15-trihydroxyeicosatrienoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

11,12,15-trihydroxyeicosatrienoic acid (11,12,15-THETA) is a bioactive lipid, a type of **hydroxy fatty acid**, derived from the metabolism of arachidonic acid by the enzyme **cytochrome P450**. It plays a crucial role in various physiological and pathological processes.

**Why is it important for research?**

1. **Inflammatory response:** 11,12,15-THETA is a potent **pro-inflammatory mediator**. It contributes to inflammation by activating various signaling pathways, including the nuclear factor kappa B (NF-κB) pathway. Research focuses on understanding its role in inflammatory diseases like arthritis, asthma, and inflammatory bowel disease.

2. **Cardiovascular health:** Studies suggest that 11,12,15-THETA can influence cardiovascular function. It has been linked to **vasoconstriction** and **platelet aggregation**, which could contribute to the development of atherosclerosis and other cardiovascular diseases.

3. **Neuroprotection:** Some research suggests that 11,12,15-THETA might have **neuroprotective effects**. It has been shown to inhibit the production of reactive oxygen species (ROS) and protect neurons from damage. However, more research is needed to confirm these findings.

4. **Cancer research:** Research into the role of 11,12,15-THETA in cancer is ongoing. Some studies suggest it may be involved in **tumor growth and metastasis**. Further research is needed to elucidate its specific role and potential as a therapeutic target.

5. **Drug development:** Due to its significant biological activity, 11,12,15-THETA is a promising target for developing new drugs. Research focuses on developing **inhibitors or modulators** of 11,12,15-THETA synthesis or its signaling pathways to treat inflammatory, cardiovascular, and neurodegenerative diseases.

**Overall, 11,12,15-THETA is a fascinating molecule with diverse biological roles. Continued research is crucial for understanding its exact functions, interactions with other molecules, and potential therapeutic applications.**

11,12,15-trihydroxyeicosatrienoic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6439610
SCHEMBL ID9301740
SCHEMBL ID9301742
MeSH IDM0181382

Synonyms (9)

Synonym
(5e,8e,13e)-11,12,15-trihydroxyicosa-5,8,13-trienoic acid
11,12,15-trihydroxy-5,8,13-eicosatrienoic acid
5,8,13-eicosatrienoic acid, 11,12,15-trihydroxy-
11,12,15-teta
11,12,15-trihydroxyeicosatrienoic acid
82144-59-0
SCHEMBL9301740
SCHEMBL9301742
11,12,15-trihydroxyeicosatrienoate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (20.00)18.2507
2000's8 (80.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.42 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]